Showing results (11-20 of 148) with videos related to
Sort By:
Pageof 15
Journal of Clinical Psychopharmacology|March 23, 2002
In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycinZeruesenay Desta, Nadia Soukhova, David A FlockhartArchives of Internal Medicine|February 28, 2002
Implications of cytochrome P450 interactions when prescribing medication for hypertensionDavid A Flockhart, Jose E Tanus-SantosBreast Cancer Research and Treatment|March 11, 2011
Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancerWenjie Jessie Lu, Zeruesenay Desta, David A FlockhartJournal of Clinical Psychopharmacology|June 23, 2012
Reduced methadone clearance during aromatase inhibitionWenjie Jessie Lu, Nancy Thong, David A FlockhartDrug Metabolism and Disposition: the Biological Fate of Chemicals|September 30, 2010
In vitro cytochrome P450-mediated metabolism of exemestaneLandry K Kamdem, David A Flockhart, Zeruesenay DestaSeminars in Perinatology|October 6, 2014
Is personalized medicine achievable in obstetrics?Sara K Quinney, Avinash S Patil, David A FlockhartJournal of Medical Case Reports|October 12, 2011
Methadone adverse reaction presenting with large increase in plasma methadone binding: a case seriesWenjie J Lu, Weidong Zhou, Yvonne Kreutz, et al.Journal of Breath Research|December 22, 2012
Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?David L Thacker, Anil Modak, David A Flockhart, et al.Clinical Pharmacokinetics|September 12, 2002
Clinical significance of the cytochrome P450 2C19 genetic polymorphismZeruesenay Desta, Xiaojiong Zhao, Jae-Gook Shin, et al.Cancer Chemotherapy and Pharmacology|February 10, 2009
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitroSeongwook Jeong, Margaret M Woo, David A Flockhart, et al.Pageof 15